JP6035627B2 - β型リン酸三カルシウムからなる生体材料 - Google Patents
β型リン酸三カルシウムからなる生体材料 Download PDFInfo
- Publication number
- JP6035627B2 JP6035627B2 JP2012179866A JP2012179866A JP6035627B2 JP 6035627 B2 JP6035627 B2 JP 6035627B2 JP 2012179866 A JP2012179866 A JP 2012179866A JP 2012179866 A JP2012179866 A JP 2012179866A JP 6035627 B2 JP6035627 B2 JP 6035627B2
- Authority
- JP
- Japan
- Prior art keywords
- ion
- tcp
- tricalcium phosphate
- ions
- biomaterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims description 121
- 235000019731 tricalcium phosphate Nutrition 0.000 title claims description 34
- 239000012620 biological material Substances 0.000 title claims description 30
- 239000001506 calcium phosphate Substances 0.000 title claims description 28
- 229910000391 tricalcium phosphate Inorganic materials 0.000 title claims description 27
- 229940078499 tricalcium phosphate Drugs 0.000 title claims description 27
- 239000011575 calcium Substances 0.000 claims description 50
- 239000000919 ceramic Substances 0.000 claims description 28
- 150000002500 ions Chemical class 0.000 claims description 27
- 229910001415 sodium ion Inorganic materials 0.000 claims description 26
- 229910004283 SiO 4 Inorganic materials 0.000 claims description 19
- 150000001768 cations Chemical class 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 17
- 150000001450 anions Chemical class 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 2
- 229910001416 lithium ion Inorganic materials 0.000 claims description 2
- 229910001437 manganese ion Inorganic materials 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- 239000006104 solid solution Substances 0.000 description 44
- -1 vanadate ion Chemical class 0.000 description 44
- 229910052710 silicon Inorganic materials 0.000 description 33
- 239000010703 silicon Substances 0.000 description 33
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 32
- 239000011777 magnesium Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 239000011734 sodium Substances 0.000 description 20
- 229910052708 sodium Inorganic materials 0.000 description 18
- 229910052911 sodium silicate Inorganic materials 0.000 description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 17
- 239000013078 crystal Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 229910021645 metal ion Inorganic materials 0.000 description 14
- 230000008859 change Effects 0.000 description 12
- 238000010304 firing Methods 0.000 description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 12
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 12
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 11
- 229910052749 magnesium Inorganic materials 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000005452 bending Methods 0.000 description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000003462 bioceramic Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000011164 ossification Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000004568 cement Substances 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000013001 point bending Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000005245 sintering Methods 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 229940032158 sodium silicate Drugs 0.000 description 3
- 235000019794 sodium silicate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000007088 Archimedes method Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010813 internal standard method Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CVPJXKJISAFJDU-UHFFFAOYSA-A nonacalcium;magnesium;hydrogen phosphate;iron(2+);hexaphosphate Chemical compound [Mg+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Fe+2].OP([O-])([O-])=O.OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O CVPJXKJISAFJDU-UHFFFAOYSA-A 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940085991 phosphate ion Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052591 whitlockite Inorganic materials 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001028 reflection method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
<<実施形態1>>
<実施形態1:概要>
<実施形態1:構成>
(1)固溶形態
(リン酸三カルシウムの性質)
(β-TCPの結晶構造)
[表1]
[表2]
(金属イオン固溶β-TCP)
(ケイ酸イオンの生体反応)
(マグネシウムイオンの生体反応)
(ナトリウムイオンの生体反応)
(本発明の目的)
(2)ナトリウム及びケイ素(またはナトリウムイオン及びケイ酸イオン)同時固溶β-TCP(NaMg-β-TCPSi)粉末の合成
[表3]
[表4]
(3)ナトリウム及びケイ素同時固溶β-TCP(NaMg-β-TCPSi)焼結体の作製
<実施形態1:置換効果>
(1)X線回折
(2)FT-IR
(3)格子定数の精密化
[数1]
(4)まとめ
(1)結晶相の同定
(2)焼成体積収縮率
(3)焼結体の曲げ強度測定
[数2]
(4)アルキメデス法による開気孔率及びかさ密度の測定
[数3]
(5)微構造観察
(6)まとめ
Claims (8)
- 四価陰イオンとしてβ型リン酸三カルシウム構造内のリン酸(PO4 3-)位置に少なくともケイ酸(SiO4 4-)イオンを置換固溶し、さらに同時に結晶の電荷補償のためにβ型リン酸三カルシウム構造内の陽イオン位置の空孔に一価陽イオンとしてナトリウムイオンを固溶し、さらに同時にβ型リン酸三カルシウム構造内のCa(5)サイトにカルシウムイオンよりイオン半径の小さい二価陽イオンを固溶したβ型リン酸三カルシウムからなる生体材料セラミックス。
- 前記二価陽イオンは、マグネシウムイオン、マンガンイオン、亜鉛イオンである請求項1に記載の生体材料セラミックス。
- さらにナトリウムイオン以外の一価陽イオンをβ型リン酸三カルシウム構造内に固溶した請求項1又は2に記載の生体材料セラミックス。
- 前記一価陽イオンは、リチウムイオン、カリウムイオン、銀イオンである請求項3に記載の生体材料セラミックス。
- 請求項1から4のいずれか一に記載のβ型リン酸三カルシウムの焼結体からなる生体材料セラミックス。
- 請求項1から4のいずれか一に記載の生体材料セラミックスであって、その性状が粉体である生体材料セラミックス。
- 請求項1から4のいずれか一に記載の生体材料セラミックスであって、その性状が顆粒体である生体材料セラミックス。
- 請求項1から4のいずれか一に記載の生体材料セラミックスであって、その性状が膜状である生体材料セラミックス。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012179866A JP6035627B2 (ja) | 2012-08-14 | 2012-08-14 | β型リン酸三カルシウムからなる生体材料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012179866A JP6035627B2 (ja) | 2012-08-14 | 2012-08-14 | β型リン酸三カルシウムからなる生体材料 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014036733A JP2014036733A (ja) | 2014-02-27 |
JP6035627B2 true JP6035627B2 (ja) | 2016-11-30 |
Family
ID=50285327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012179866A Active JP6035627B2 (ja) | 2012-08-14 | 2012-08-14 | β型リン酸三カルシウムからなる生体材料 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6035627B2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6109773B2 (ja) * | 2014-03-14 | 2017-04-05 | 学校法人千葉工業大学 | 生体材料セラミックス焼結体及びその製造方法 |
JP2018171080A (ja) * | 2015-08-28 | 2018-11-08 | 株式会社福山医科 | 代用骨ブロック、代用骨ブロックの製造方法 |
WO2018181245A1 (ja) * | 2017-03-30 | 2018-10-04 | 学校法人千葉工業大学 | 硬組織接合用接着剤、硬組織接合用接着剤キット、及び骨セメント |
JP7097544B2 (ja) | 2017-03-30 | 2022-07-08 | 学校法人千葉工業大学 | 硬組織接合用接着剤、硬組織接合用接着剤キット、及び骨セメント |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6061415B2 (ja) * | 2010-04-30 | 2017-01-18 | 学校法人千葉工業大学 | β型リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 |
-
2012
- 2012-08-14 JP JP2012179866A patent/JP6035627B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014036733A (ja) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kalita et al. | Nanocrystalline calcium phosphate ceramics in biomedical engineering | |
Hidouri et al. | Thermal behavior, sintering and mechanical characterization of multiple ion-substituted hydroxyapatite bioceramics | |
TWI543770B (zh) | 礦化膠原蛋白與生物陶瓷之複合物及其製造方法 | |
JP6663608B2 (ja) | 骨欠損再建治療用キット、医療用硬組織再建材、製品無機化合物の製造方法及び製品無機化合物 | |
Cicek et al. | Alpha-tricalcium phosphate (α-TCP): solid state synthesis from different calcium precursors and the hydraulic reactivity | |
US20210100930A1 (en) | Whitlockite coating constructed on surface of calcium phosphate-based bioceramic substrate and preparation method therefor | |
KR20110139246A (ko) | 갈륨화된 칼슘 포스페이트 생체적합 물질 | |
Shirazi et al. | Ion size, loading, and charge determine the mechanical properties, surface apatite, and cell growth of silver and tantalum doped calcium silicate | |
JP6035627B2 (ja) | β型リン酸三カルシウムからなる生体材料 | |
Sanyal et al. | Synthesis, characterization and in-vitro studies of strontium-zinc co-substituted fluorohydroxyapatite for biomedical applications | |
Singh et al. | Synthesis and characterization of bioactive zirconia toughened alumina doped with HAp and fluoride compounds | |
Nandha Kumar et al. | Formation mechanisms in β-Ca3 (PO4) 2–ZnO composites: structural repercussions of composition and heat treatments | |
Lin et al. | Novel highly bioactive and biodegradable gypsum/calcium silicate composite bone cements: from physicochemical characteristics to in vivo aspects | |
JP6109773B2 (ja) | 生体材料セラミックス焼結体及びその製造方法 | |
JP6061415B2 (ja) | β型リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 | |
TWI573776B (zh) | 磷酸二鈣陶瓷、磷酸二鈣與氫氧基磷灰石之雙相陶瓷及其製造方法 | |
Zhang et al. | Synthesis and structural characteristics of magnesium and zinc doped hydroxyapatite whiskers | |
JP5898877B2 (ja) | β型リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 | |
JP6035623B2 (ja) | 三価金属イオンの固溶量によるリン酸三カルシウムからなる生体材料セラミックスの溶解性及び焼結性の制御方法 | |
RU2546539C1 (ru) | Способ получения порошкового материала на основе карбонатгидроксиапатита и брушита | |
WO2013029185A1 (en) | Magnesium phosphate biomaterials | |
Pijocha et al. | Physicochemical properties of the novel biphasic hydroxyapatite–magnesium phosphate biomaterial | |
Yang et al. | Regulating the multifactor during wet chemical synthesis to obtain calcium phosphate powders with controllable phase purity for bone repair | |
Abbasi-Shahni et al. | Mechanical properties and in vitro bioactivity of β-tri calcium phosphate, merwinite nanocomposites | |
RU2395303C1 (ru) | Способ получения керамического композиционного биодеградируемого материала на основе двойного фосфата калия кальция |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150807 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160812 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161013 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6035627 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |